Atlas Trials

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Clinical trial NCT07689175 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07689175
Sponsor
University of Texas Southwestern Medical Center
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2026-10-31
Primary completion
2031-10-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.